Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
$0.00
$0.00
$0.00
N/A1.86200 shsN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
$1.80
+7.8%
$1.87
$1.58
$16.18
$260K-0.8324,747 shs221,699 shs
Futureworld Corp. stock logo
FWDG
Futureworld
$0.00
$0.00
$0.00
N/A0.34666,666 shs666,666 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
VIVUS, Inc. stock logo
VVUSQ
VIVUS
$0.12
$0.12
$0.07
$4.55
N/AN/AN/AN/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
+7.78%+1.69%-1.10%-23.08%+179,999,900.00%
Futureworld Corp. stock logo
FWDG
Futureworld
0.00%0.00%0.00%0.00%0.00%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
VIVUS, Inc. stock logo
VVUSQ
VIVUS
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Futureworld Corp. stock logo
FWDG
Futureworld
N/AN/AN/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
VIVUS, Inc. stock logo
VVUSQ
VIVUS
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00
N/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
0.00
N/AN/AN/A
Futureworld Corp. stock logo
FWDG
Futureworld
0.00
N/AN/AN/A
NSPX
Inspyr Therapeutics
0.00
N/AN/AN/A
VIVUS, Inc. stock logo
VVUSQ
VIVUS
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
$44.88M0.01N/AN/A($19.40) per share-0.09
Futureworld Corp. stock logo
FWDG
Futureworld
N/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
VIVUS, Inc. stock logo
VVUSQ
VIVUS
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
-$2.56MN/A0.00N/AN/AN/AN/AN/A
Futureworld Corp. stock logo
FWDG
Futureworld
N/AN/A0.00N/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A
VIVUS, Inc. stock logo
VVUSQ
VIVUS
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
N/AN/AN/AN/AN/A
Futureworld Corp. stock logo
FWDG
Futureworld
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A
VIVUS, Inc. stock logo
VVUSQ
VIVUS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
0.28
1.14
0.47
Futureworld Corp. stock logo
FWDG
Futureworld
N/AN/AN/A
NSPX
Inspyr Therapeutics
N/A
0.09
0.09
VIVUS, Inc. stock logo
VVUSQ
VIVUS
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
2.55%
Futureworld Corp. stock logo
FWDG
Futureworld
N/A
NSPX
Inspyr Therapeutics
0.02%
VIVUS, Inc. stock logo
VVUSQ
VIVUS
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
20N/AN/ANot Optionable
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
38160,00090,000N/A
Futureworld Corp. stock logo
FWDG
Futureworld
8N/AN/ANot Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable
VIVUS, Inc. stock logo
VVUSQ
VIVUS
57N/AN/ANot Optionable

Recent News About These Companies

VIVUS’ QSYMIA® to be Featured on Health Uncensored with Dr. Drew
VI-0810 by Vivus for Diabetes: Likelihood of Approval
The Albion reopens following £6m refurb

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anthera Pharmaceuticals stock logo

Anthera Pharmaceuticals OTCMKTS:ANTH

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Capstone Therapeutics stock logo

Capstone Therapeutics NASDAQ:CAPS

$1.80 +0.13 (+7.78%)
As of 06/30/2025 04:00 PM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Futureworld stock logo

Futureworld OTCMKTS:FWDG

FutureWorld Corp., together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of hemp/cannabis products, services, and technologies worldwide. The company provides smart sensor technology, communication network, surveillance security, data analysis for smart cultivation, and consultation for the industrial hemp and legal medicinal marijuana. It offers personal and professional tetrahydrocannabinoil and Cannabidiol test kits; pharmaceutical grade CBD oil solutions; URVape vaporizer pens, which are oil vaporizers for the e-cigarette, cannabis, and herbal vaping industry; CaNNaLyTiX, a dashboard controller system that allows various computer systems to be integrated throughout a cultivator's infrastructures; CaNNaTRAK, the barcode and RFID tracking systems for keeping seed to sale tracking of hemp/cannabis; and SPIDer (secure perimeter intrusion detection network), a system to meet the needs of theft and malicious attacks. The company also provides SmartSense, which offers wireless security and smart sensor mesh network for precision agriculture, irrigation systems, and greenhouses for the hemp industry; SmartNergy that offers tools to analyze various aspects of a cultivator's energy usage; and CaNNaBoX machine, which operates with the swipe of a card to verify identity, age, and prescription information of a medical marijuana patient before releasing measured packages of marijuana. Its target customers include consumers via Internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, affiliate sales, and master distributors. The company was formerly known as FutureWorld Energy, Inc. and changed its name to FutureWorld Corp. in June 2014. FutureWorld Corp. was founded in 2002 and is based in Saint Petersburg, Florida.

Inspyr Therapeutics OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

VIVUS stock logo

VIVUS OTCMKTS:VVUSQ

$0.12 0.00 (0.00%)
As of 12/17/2020

VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.